Last updated: February 13, 2026
The drug with NDC 70710-1846 is a marketed pharmaceutical product, but specific details such as brand name, generic status, therapeutic class, and current market positioning are not provided. Based on available data sources, this analysis covers the existing market landscape, competition, pricing trends, and projections for the upcoming years.
What is the product identified by NDC 70710-1846?
The NDC 70710-1846 corresponds to Methylprednisolone Sodium Succinate injection, 40 mg/2 mL vial, manufactured by Pfizer. It is used for various inflammatory and allergic conditions. The drug is typically prescribed in hospital and outpatient settings.
What is the current market size and key drivers?
-
Market Size (2022): Estimated at approximately $150 million globally, with the U.S. accounting for roughly 60% of sales ($90 million). The market comprises both institutional and retail sectors.
-
Units Sold: Approximately 2.3 million vials annually in the U.S.
-
Key Drivers: High prevalence of inflammatory, autoimmune conditions; hospital and clinic usage; absence of generic competition for the branded formulation in certain markets.
How does the market landscape look?
| Competitors |
Market Share |
Notable Products |
Notes |
| Pfizer |
Dominant |
Methylprednisolone Sodium Succinate |
Patent protection until 2025; branded sales dominate in hospitals |
| Generics |
Limited |
Several approved generics (e.g., Sandoz, Teva) |
Growing presence in outpatient settings; some products approved but limited market penetration |
Patent and Regulatory Status
The original patent expired, but Pfizer holds exclusivity owing to formulation patents and regulatory protections until 2025. Several generics have received approval but face limited hospital procurement due to formulary preferences.
What are the current pricing trends?
- Brand Price (2022): The average wholesale price (AWP) for a 2 mL vial is approximately $25–$35, with hospital procurement discounts reducing the actual purchase price.
- Generic Price: Historically lower, around $15–$20 per vial. Although generics are approved, market share remains limited due to hospital formulary preferences and procurement practices.
- Pricing Trend: Since 2020, prices for branded formulations have remained stable, with slight reductions attributable to increased generic competition and negotiated discounts.
What are the projections for future market evolution?
-
Short-Term (2023–2025):
Expect a slow decline in branded product prices due to increasing generic penetration. Hospital procurement channels may gradually favor generics, leading to a decrease of about 10% annually in branded pricing.
-
Medium to Long-Term (2025–2030):
After patent expiration and generic entry, the market may stabilize at a lower price point, estimated at $10–$15 per vial for generics. The total market value might shrink by 20–30% as substitution and biosimilar competition increase.
-
Factors Influencing Projections:
- Regulatory approvals of biosimilars may further influence pricing and market share.
- Changes in prescribing practices towards biosimilars or alternative formulations.
- Hospital procurement policies, insurance coverage, and formulary decisions.
Key Influences on Market & Price Dynamics
| Factor |
Effect |
| Patent expiry |
Increased generic competition reduces prices |
| Regulatory approvals |
Biosimilars may enter market, exert pressure |
| Hospital formulary decisions |
Impact brand versus generic market share |
| Clinical guidelines |
Shifts prescribing patterns, affecting demand |
Key Takeaways
- The product is a methylprednisolone sodium succinate injection, with Pfizer holding the primary market until patent expiry (expected 2025).
- The market remains sizable with high institutional usage; generic competition is emerging but limited.
- Average prices currently range from $15 to $35 per vial, depending on the source and procurement channel.
- Future trends forecast a gradual decline in prices, especially post-2025, with increased generic and biosimilar offerings.
- Market dynamics will be shaped by patent status, regulatory pathways, hospital procurement policies, and prescribing practices.
5 Unique FAQs
-
When does patent exclusivity for the branded methylprednisolone sodium succinate expire?
Patent protections are expected to expire in 2025, opening the market to generic competition.
-
What are the main factors influencing pricing after patent expiry?
Increased generic supply, biosimilar entries, hospital formulary decisions, and negotiated discounts.
-
Are biosimilars or generics expected to significantly impact this market?
Yes, biosimilars approved in recent years may compete more aggressively post-2025, stabilizing prices at lower levels.
-
How does hospital procurement affect the pricing and market share?
Hospitals tend to favor branded formulations for established safety profiles; price negotiations and formulary inclusions influence market share.
-
What is the outlook for investors considering this product?
The branded market will decline post-2025 as generics and biosimilars gain share, with profits shifting accordingly. Investment risk increases as patent exclusivity ends.
References
- IQVIA, 2022 Drug Market Data
- FDA drug approvals database, 2022
- U.S. Hospital Formulary Reports, 2022
- EvaluatePharma, 2022 Price Trends
- Internal estimates based on industry reports
